Pepsin and the esophagus

Yale Journal of Biology and Medicine

Volumn 72, Issue 2-3, 1999, Pages 133-143

  Hirschowitz, Basil I ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PEPSIN A; PROTON PUMP INHIBITOR; RANITIDINE;

ACIDITY; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS MUCOSA; ESOPHAGUS PH; HUMAN; REVIEW; STOMACH ACID SECRETION; STOMACH JUICE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DISEASE MODELS, ANIMAL; ESOPHAGITIS; ESOPHAGOGASTRIC JUNCTION; GASTRIC JUICE; HUMANS; MUCOUS MEMBRANE; OMEPRAZOLE; PEPSIN A;

EID: 0033491842     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Lanas, A.I., Sousa, F.L., Ortego, J., Esteva, F., Blas, J.M., Soria, J., and Sainz, R. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin. Eur. J. Gastroenterol. Hepatol. 7:1065-1072, 1995.
2. Lanas, A.I., Blas, J.M., Ortego, J., Soria J., and Sainz, R. Adaptations of esophageal mucosa to acid- and pepsin-induced damage: role of nitrous oxide and epidermal growth factors. Dig. Dis. Sci. 42:1003-1012, 1997.
3. Goldberg, H.I., Dodds, W.J., Gee, S., Montgomery, C., and Zboraski, F.F. Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 56:223-233, 1969.
4. Hirschowitz, B.I. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 101:1149-1158, 1991.
5. 2 antagonists. Scand. J. Gastroenterol. 27:449-452, 1992.
6. Hirschowitz, B.I. Gastric acid and pepsin secretion in patients with Barrett's esophagitis and appropriate controls. Dig. Dis. Sci. 41:1384-1391, 1996.
7. Hirschowitz, B.I. Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig. Dis. Sci. 41:2115-2122, 1996.
8. Marks, R.D. and Richter, J.E. Gastroesophageal reflux disease. In: Zakim D, Dannenberg AJ, eds. Peptic Ulcer Disease and Other Acid-Related Disorders. New York: Academic Research Associates, Inc.; 1991.
9. + antiport. Gastroenterology 99:909-917, 1990.
10. Orlando, R.C. Esophageal epithelial defense against acid injury. J. Clin. Gastroenterol. 13:S1-S5, 1991.
11. Hirschowitz, B.I. Pepsin in the pathogenesis of peptic ulceration. In: Halter, F., Garner, A., and Tytgat, G.N.J., eds. Mechanisms of Peptic Ulcer Healing. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1990, pp. 183-194.
12. Ford, T.F., Grant, D.A.W., Austen, B.M., and Hermon-Taylor, J. Intramucosal activation of pepsinogens in the pathogenesis of acute gastric erosions and their prevention by the potent semisynthetic amphipathic inhibitor pepstatinyl-glycyl-lysyl-lysine. Clin. Chim. Acta 145:37-47, 1985.
13. Ohe, K., Ueno, N., Yokoya, H. and Miyoshi, A. The activation of pepsinogen inside the gastric mucosa caused by the hydrogen ion back diffusion during the course of aspirin ulceration. Hiroshima J. Med. Sci. 28:1-11, 1979.
14. Kretsina, T.F. and Miller, E.J. Isolation and characterization of basement membrane collagen from human placental tissue. Evidence for the presence of two genetically distinct collagen chains. Biochemistry 18:3089-3097, 1979.
15. Dolz, A., Engel, J., and Kuhn, H. Folding of collagen. IV. Eur. J. Biochem. 178:357-366, 1988.
16. Ingber, D. and Folkman, J. How does extracellular matrix control capillary morphogenesis? Cell 58:803-805, 1989.
17. Santucci, L., Patoia, L., Fiorucci, S., Farroni, F., Favero, D., and Morelli, A. Oesophageal lesions during treatment with piroxicam [Letter]. Br. Med. J. 300:1018, 1990.
18. Semble, E.L., Wu, W.C., Castell, D.O. Nonsteroidal anti-inflammatory drugs and esophageal injury. Semin. Arthritis Rheum. 19:99-109, 1989.
19. Taha, A.S., Dahill, S., Nakshabendi, I., Lee, F.D., Sturrock, R.D., Russel, R.I. Oesophageal histology in long-term users of non-steroidal anti-inflammatory drugs. J. Clin. Pathol. 47:705-708, 1994.
20. Lanas, A. and Hirschowitz, B.I. Significant role of aspirin use in patients with esophagitis. J. Clin. Gastroenterol. 13:622-627, 1991.
21. Hirschowitz, B.I. and Lanas, A. NSAID association with gastrointestinal bleeding and peptic ulcer. Agents Actions 35(suppl):93-101, 1991.
22. Burget, D.W., Chiverton, S., and Hunt, R. Is there an optimal degree of acid suppression for healing of duodenal ulcers. Gastroenterology 99:345-349, 1990.
23. Bell, N.V.J., Burger, D., Howden, C.W., Wilkerson, J. and Hunt, R.H. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 51:59-63, 1991.
24. Hirschowitz, B.I. Medical management of esophageal reflux. Yale J. Biol. Med. 1994; 67:223-231.
25. Klinkenberg-Knol, E.C., Jansen, J.B., Lamers, C.B., Nelis, F., Snel, P., and Meuwissen, S.G. Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scand. J. Gastroenterol. 166:88-93, 1989.
26. 2-receptor antagonists. Aliment. Pharmacol. Therap. 4:145-155, 1990.
27. Hallerback, B., Unge, P., Carling, L., Edwin, B., Glise, H., Havu, N., Lyrenas, E., and Lundberg, K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 107:1305-1311, 1994.
28. Sontag, S.J., Hirschowitz, B.I., Holt, S., Robinson, M.G., Behar, J., Berenson, M.M., McCullough, A., Ippoliti, A.F., Richter, J.E., Ahtaridis, G., McCallum, R.W., Pambianco, D.J., Vlahcevic, R.Z., Johnson, D.A., Collen, M.J., Lyon, D.T., Humphries, T.J., Cagliola, A., and Berman, R.S. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 102:109-118, 1992.
29. Klinkenberg-Knoll, E.C., Festen, H.P.M., Jansen, J.B.M.J., Lamers, C.B., Nelis, S., Luckers, A., Dekkers, C.P., Havu, N., and Meuwissen, S.G. Long-term treatment with omeprazole for refractory esophagitis: efficacy and safety. Ann. Int. Med. 121:161-167, 1994.
30. Sontag, S.J., Robinson, M., Hirschowitz, B.I., Sabesin, S.M., Wu, W.C., Behar, J., Peterson, W.L., Kranz, K.R., Tarnawski, A., Dayal, Y., Berman, R., and Simon, T.J. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study. Aliment. Pharmacol. Therap. 11:373-80, 1997.
31. Dent, J., Yeomans, N.D., Mackinnon, M., Reed, W., Narielvala, P.M., Hetzel, D.J., Solcia, E., and Shearman, D.J. Omeprazole vs. ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut 35:590-598, 1994.
32. Walt, R.P., Gomes. M.D., Wood, E.C., Logan, L.H., and Pounder, R.E. Effect of daily oral omeprazole on 24-hour intragastric acidity. Br. Med. J. 287:12-14, 1983.
33. Klinkenberg-Knoll, E.C. and Meuwissen, S.G.M. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment. Pharmacol. Ther. 4:485-495, 1990.
34. Roland, M., Berstadt, A., and Liavag, T. Effect of carbacholine and urecholine on pentagastrin-stimulated gastric secretion in healthy subjects. Scand J Gastroenterol 10:357-362, 1975.